Your browser doesn't support javascript.
loading
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Eram, Mohammad S; Shen, Yudao; Szewczyk, Magdalena; Wu, Hong; Senisterra, Guillermo; Li, Fengling; Butler, Kyle V; Kaniskan, H Ümit; Speed, Brandon A; Dela Seña, Carlo; Dong, Aiping; Zeng, Hong; Schapira, Matthieu; Brown, Peter J; Arrowsmith, Cheryl H; Barsyte-Lovejoy, Dalia; Liu, Jing; Vedadi, Masoud; Jin, Jian.
Afiliación
  • Eram MS; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Shen Y; Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Szewczyk M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Wu H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Senisterra G; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Butler KV; Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Kaniskan HÜ; Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Speed BA; Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Dela Seña C; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Dong A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Zeng H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Schapira M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Brown PJ; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
  • Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Liu J; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, M5G 2M9, Canada.
  • Vedadi M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
  • Jin J; Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
ACS Chem Biol ; 11(3): 772-781, 2016 Mar 18.
Article en En | MEDLINE | ID: mdl-26598975
Protein arginine methyltransferases (PRMTs) play a crucial role in a variety of biological processes. Overexpression of PRMTs has been implicated in various human diseases including cancer. Consequently, selective small-molecule inhibitors of PRMTs have been pursued by both academia and the pharmaceutical industry as chemical tools for testing biological and therapeutic hypotheses. PRMTs are divided into three categories: type I PRMTs which catalyze mono- and asymmetric dimethylation of arginine residues, type II PRMTs which catalyze mono- and symmetric dimethylation of arginine residues, and type III PRMT which catalyzes only monomethylation of arginine residues. Here, we report the discovery of a potent, selective, and cell-active inhibitor of human type I PRMTs, MS023, and characterization of this inhibitor in a battery of biochemical, biophysical, and cellular assays. MS023 displayed high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but was completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. A crystal structure of PRMT6 in complex with MS023 revealed that MS023 binds the substrate binding site. MS023 potently decreased cellular levels of histone arginine asymmetric dimethylation. It also reduced global levels of arginine asymmetric dimethylation and concurrently increased levels of arginine monomethylation and symmetric dimethylation in cells. We also developed MS094, a close analog of MS023, which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. MS023 and MS094 are useful chemical tools for investigating the role of type I PRMTs in health and disease.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Pirroles / Etanolaminas / Etilenodiaminas / Antineoplásicos Límite: Humans Idioma: En Revista: ACS Chem Biol Año: 2016 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Pirroles / Etanolaminas / Etilenodiaminas / Antineoplásicos Límite: Humans Idioma: En Revista: ACS Chem Biol Año: 2016 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos